8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2015

 

 

KEMPHARM, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

(State or other jurisdiction of incorporation)

 

001-36913   20-5894398
(Commission File No.)   (IRS Employer Identification No.)

2656 Crosspark Road, Suite 100

Coralville, IA 52241

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (319) 665-2575

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01 Other Events.

On August 12, 2015, members of management of KemPharm, Inc., or the Company, will present at the Canaccord Genuity 35th Annual Growth Conference on, among other things, the Company’s product candidate pipeline. A copy of this presentation is available on the Company’s website at www.kempharm.com, and is filed as Exhibit 99.1 to this Current Report on Form 8-K, the contents of which are incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit

No.

  

Description

99.1    Presentation titled “Canaccord Genuity 35th Annual Growth Conference” dated August 12, 2015.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    KEMPHARM, INC.
Date: August 12, 2015    
    By:  

/s/ R. LaDuane Clifton

      R. LaDuane Clifton
      Chief Financial Officer


EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1    Presentation titled “Canaccord Genuity 35th Annual Growth Conference” dated August 12, 2015.
EX-99.1
August 12, 2015
Canaccord
Genuity
35th Annual Growth Conference
Exhibit 99.1


2
Cautionary Note Regarding Presentation Information
This
presentation
contains
forward-looking
statements,
including
statements
about
our
plans
to
develop
and
commercialize
our
product
candidates,
our
planned
clinical
trials
for
KP201/APAP
and
our
other
prodrug
product
candidates,
the
timing
of
and
our
ability
to
obtain
and
maintain
regulatory
approvals
for
our
product
candidates,
including
expectations
about
our
ability
to
use
the
505(b)(2)
pathway
and
expedited
FDA
review,
the
clinical
utility
of
our
product
candidates
and
our
intellectual
property
position.
These
statements
involve
substantial
known
and
unknown
risks,
uncertainties
and
other
factors
that
may
cause
our
actual
results,
levels
of
activity,
performance
or
achievements
to
be
materially
different
from
the
information
expressed
or
implied
by
these
forward-looking
statements.
We
may
not
actually
achieve
the
plans,
intentions
or
expectations
disclosed
in
our
forward-looking
statements,
and
you
should
not
place
undue
reliance
on
our
forward-looking
statements.
Actual
results
or
events
could
differ
materially
from
the
plans,
intentions
and
expectations
disclosed
in
the
forward-looking
statements
we
make.
The
forward-looking
statements
in
this
presentation
represent
our
views
as
of
the
date
of
this
presentation.
These
and
other
risks
concerning
our
business
are
described
in
additional
detail
in
our
Registration
Statement
on
Form
S-1
(Registration
No.
333-202660)
declared
effective
April
15,
2015,
and
our
other
Periodic
and
Current
Reports
filed
with
the
Securities
and
Exchange
Commission.
We
anticipate
that
subsequent
events
and
developments
will
cause
our
views
to
change.
However,
while
we
may
elect
to
update
these
forward-looking
statements
at
some
point
in
the
future,
we
have
no
current
intention
of
doing
so
except
to
the
extent
required
by
applicable
law.
You
should,
therefore,
not
rely
on
these
forward-looking
statements
as
representing
our
views
as
of
any
date
subsequent
to
the
date
of
this
presentation.
This
presentation
also
contains
estimates
and
other
statistical
data
made
by
independent
parties
and
by
us
relating
to
market
size
and
other
data
about
our
industry.
This
data
involves
a
number
of
assumptions
and
limitations,
and
you
are
cautioned
not
to
give
undue
weight
to
such
estimates.
In
addition,
projections,
assumptions
and
estimates
of
our
future
performance
and
the
future
performance
of
the
markets
in
which
we
operate
are
necessarily
subject
to
a
high
degree
of
uncertainty
and
risk.
Any
information
in
this
presentation
provided
by
IMS
Health
Incorporated
(IMS)
is
an
estimate
derived
from
the
use
of
information
under
license
from
the
following
IMS
Health
information
service:
IMS
National
Sales
Perspectives
and
NPA
Audits,
in
each
case,
for
the
period
of
January
2011
to
September
2014.
IMS
expressly
reserves
all
rights,
including
rights
of
copying,
distribution
and
republication.


3
KemPharm Overview
Specialty pharmaceutical company discovering and developing novel
prodrugs
Leverage
LAT Platform Technology to improve the attributes of approved
drugs in large markets
o
505(b)(2) pathway reduces risk and expense
o
Composition-of-matter patent protection
KP201/APAP has the potential to be the first FDA approved abuse-
deterrent IR hydrocodone/APAP product (NDA submission in 2H 2015)
o
IR hydrocodone is the highest prescribed opioid in the U.S.
Pipeline of product candidates in pain, ADHD and other CNS disorders


4
Management Team
Travis C. Mickle, PhD
President and CEO
Gordon K. Johnson
CBO
Tracy M. Woody
CCO
R. LaDuane Clifton      
CFO
Sven Guenther, PhD
EVP of R&D


5
Ligand Activated Therapy (LAT) Platform Technology
1)
Select FDA-approved and widely prescribed drug for improvement
2)
Chemically modify using a ligand to create a prodrug
o
Ligands –
GRAS or demonstrated to be safe
o
Prodrugs generate composition-based patents
3)
Following ingestion, normal human metabolic processes cleave the ligand
and release the active drug
Proprietary to KemPharm
and is applicable across therapeutic areas
Amenable to both immediate and extended release formulations
Approved Drug with
Sub-Optimal
Properties
Prodrug with
Improved Attributes
Cleaved Drug through
Human Metabolic
Process
Ligand
LAT
LAT
LAT


6
Pipeline of Multiple Product Candidates
Selected KemPharm Prodrug Product Candidates
Indication / Parent Drug
Product Candidate
Development Status
Key Milestone
Pain
Hydrocodone (IR)
KP201/APAP 
Clinical Trials
NDA Filing – 2H 2015
Hydromorphone (ER)
KP511/ER
Preclinical
Human POC Data – 2016
Oxycodone (ER)
KP606/ER
Preclinical
Human POC Data – 2017
ADHD
Methylphenidate
(controlled release) 
KP415
Preclinical
Human POC Data – 2016
Multiple CNS Disorders
Quetiapine
KP303
Preclinical
Preclinical Development
Multiple Other Compounds in Pre-Discovery Stage


7
Advancing Opioid Abuse-Deterrent Technology
High Tamper
Resistance
KemPharm’s
Molecular
Based Abuse-Deterrent
Technology
Crushing or Physical
Manipulation
Extraction
Chemical
Hydrolysis
Neutralization
and/or
Isolation
Many Formulation-
Based Abuse-Deterrent
Opioids
Crushing or Physical
Manipulation
Extraction
Traditional Opioids
No Tamper
Resistance
Number
and
complexity
of
steps
required
to
access
abusable
opioids


8
Opioid Abuse-Deterrent Landscape
KemPharm
Prodrugs
OxyContin
TARGINIQ
EMBEDA
Hysingla 
Parent Drug
Multiple 
IR/ER Opioids
ER 
Oxycodone
ER 
Oxycodone
ER 
Morphine
ER 
Hydrocodone
Resists Physical Tampering
Resists Non-Oral Abuse
Molecular-Based Deterrence
x
x
x
x
Prevents Common Solvent
Extraction
x
x
x
x
Potentially Prevents Oral Abuse
x
x
x
x


9
Treatment of Acute Moderate to Moderately Severe Pain
KP201/APAP Overview


10
KP201/APAP Product Features
Molecular-Based Abuse-Deterrent Technology
Composition-of-Matter Patent Protection Until 2031
No Generic Equivalent Product (Benzhydrocodone)
Prodrug composed of hydrocodone and a generally regarded as safe (GRAS) ligand
Convenient Dosing
Planned NDA submission in 2H 2015 with priority review anticipated
Successfully completed bioequivalence trial in humans


11
Bioequivalence
Study
KP201.102
(KP201/APAP
vs.
Norco
®
)
Hydrocodone/Hydromorphone
Acetaminophen
C
max
AUC
0-t
AUC
inf
T
max
87%
94%
94%
102%
92%
100%
90%
120%
C
max
AUC
0-t
AUC
inf
T
max
APAP
92%
102%
99%
98%
Note:
HC refers to hydrocodone.
HM refers to hydromorphone, the active metabolite of hydrocodone.
0
50
100
150
200
250
300
350
400
450
500
0
4
8
12
16
20
24
Time [hours]
0
5,000
10,000
15,000
20,000
1
×7.5/325 mg Norco
(HC)
1
×6.67/325 mg
KP201/APAP (HC)
1
×7.5/325 mg Norco
(HM)
1
×6.67/325 mg
KP201/APAP (HM)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
0
4
8
12
16
20
24
Time [hours]
1
×7.5/325 mg Norco
1
×6.67/325 mg KP201/APAP
Hydrocodone
Hydromorphone


12
KP201/APAP Tamper Resistant Properties –
In Vitro Studies
Extraction of API (KP201) only yields inactive prodrug
Hydrocodone not released through:
o
Physical manipulation (e.g., grinding)
o
Common solvent extraction (e.g., “alcohol dose dumping”, “cold water
extraction”)
KP201 is chemically stable under commonly applied “extraction methods”
Hydrolysis under very harsh conditions is not practical
o
KP201 partially hydrolyzes under highly basic/acidic conditions
o
Poor solubility in blood, water and other solvents render it unsuitable for
IV administration


13
KP201 Solvent Hydrolysis Studies
Solvent
% Release of Hydrocodone
Ambient Temperature
At Boiling Point
0.5 hours
1 hour
4 hours
0.5 hours
1 hour
4 hours
Water
0
0
0
0
0
0
Ethanol
0
0
0
0
0
0
Methanol
0
0
0
0
0
0
Acetone
0
0
0
0
0
0
Ethyl acetate
0
0
0
0
0
0
Toluene
0
0
0
0
0
0
Xylene
0
0
0
0
0
0
Tetrahydrofuran
0
0
0
0
0
0
Methy ethyl ketone
0
0
0
0
0
0
Octane
0
0
0
0
0
0
Petrol ether
0
0
0
0
0
0
Preliminary results suggest that KP201 remains intact and does not hydrolyze or
break down into its components in commonly available solvents


14
KP201 Abuse-Deterrent Properties in Rat Studies
Note: HC·BT refers to hydrocodone bitartrate.
Intranasal
Intravenous
0
1,000
2,000
3,000
4,000
0.0
0.2
0.4
0.6
0.8
1.0
Time [hours]
HC·BT (25.5 mg/kg HC eq.)
KP201 (0.2 mg/kg HC eq.)
0
100
200
300
400
500
0.0
0.2
0.4
0.6
0.8
1.0
Time [hours]
HC·BT (2.0 mg/kg HC eq.)
KP201 (2.0 mg/kg HC eq.)


15
Recently Completed KP201.A01 Human Abuse Liability Trial
Oral Human Abuse Liability Trial
o
Compared the drug likability, exposure levels and safety of
KP201/APAP compared to Norco after oral administration
o
Single-center, randomized, double-blind, active-
and placebo-controlled
crossover trial (62 subjects completed the study)
Positive data announced on June 11, 2015
o
Lower exposure to hydrocodone at the highest dose levels
o
Lower incidence of hypoxia across the same dosage levels, suggestive
of the potential for improved safety
o
Liking data was similar at each equivalent dose level, as expected


16
Ongoing Human Abuse Liability and PK Trials
Intranasal Human Abuse Liability Trial
o
Assesses the drug likability, exposure levels and safety of KP201/APAP
compared to Norco after crushing and intranasal administration
o
Single-center, randomized, double-blind trial (n=40)
o
Data in 3Q 2015
Intranasal KP201 (API) PK Trial
o
Assesses the drug exposure levels
of KP201 (API) compared to
hydrocodone bitartrate
after intranasal administration
o
Single-center, randomized, double-blind trial (n=24)
o
Data in 3Q 2015


17
KP201/APAP Potential Abuse-Deterrent Label Claims
The FDA outlines 3 types of
studies that may translate into 4
categories of label claims
KemPharm’s abuse liability
program is consistent with the
FDA Guidance:
o
Extraction/hydrolysis study
o
Oral abuse liability
trial
(with pharmacokinetics)
o
Intranasal abuse liability trial
(with pharmacokinetics)
KP201/APAP will be compared
with Norco
®
in all studies
Studies will be completed
before filing of NDA
If data is positive, label may
include claims for up to 3
categories at approval
FDA Guidance
1.
Laboratory manipulation and extraction studies (Category 1)
2.
Pharmacokinetic studies (Category 2)
3.
Clinical abuse potential studies (Category 3)
There are four general categories of claims available to describe the potential abuse-deterrent
properties of a product.  Depending on product and study data, a combination of categories can
be
included
in
the
label
claims.
The
FDA
Guidance
lists
the
following
theoretical
examples:
Category 1:
In vitro data demonstrate the product has physical and chemical
properties that are expected to deter intravenous abuse.
1
Category 1 and 2:
In
vitro
data
demonstrate
that
the
product
has
physical
and
chemical
properties that are expected to deter oral, nasal and intravenous abuse.
1
Category 2 and 3:
Pharmacokinetic and clinical abuse potential studies indicate that the
product has properties that are expected to deter abuse via the oral,
intranasal and intravenous routes.
1
Category 4:
Data demonstrated a reduction in the abuse of the product in
the community
1
1
Abuse of the product is still possible by other routes


18
Large Market Opportunity
Hydrocodone is associated with more drug abuse and diversion than any
other licit or illicit opioid
(1)
IR hydrocodone in combination with acetaminophen is the most frequently
prescribed opioid in the U.S.
(2)
o
IR hydrocodone/APAP products accounted for 127.4 million prescriptions
in the U.S. in 2013
(2)
o
Assuming 14 days therapy prescribed and QID dosing, 127.4 million
prescriptions translates into over 7 billion tablets per year
(1)
DEA website.
(2)
IMS Health Incorporated.


19
KP201/APAP Commercial Strategy
Potential global / U.S.-based
deal targeting large prescriber
base, including primary care
physicians
Utilize contract sales force(s)
Collaboration
Specialist sales force targeting
pain thought leaders, pain
management specialists and
high prescribing health care
professionals
License international commercial
rights to one or more
collaborators
Specialist U.S. Sales Force
KemPharm
has many potential avenues to commercialize KP201/APAP, including but not
limited to, a collaboration or establishing a specialist U.S. sales force


20
State Legislative Initiatives
AL
AL
AZ
AZ
AR
AR
CA
CA
CO**
CO**
FL
FL
GA
GA
ID
ID
IL
IL
IN
IN
IA
IA
KS
KS
KY
KY
LA
LA
ME
ME
MA 
MA 
MI
MI
MN
MN
MS
MS
MO
MO
MT
MT
NE
NE
NV
NV
NH*
NH*
NM*
NM*
NY
NY
NC
NC
ND
ND
OH
OH
OK
OK
OR
OR
PA
PA
SC
SC
SD
SD
TN**
TN**
TX
TX
UT**
UT**
VT 
VT 
VA*
VA*
WA
WA
WV*
WV*
WI
WI
WY
WY
CT
CT
DE
DE
MD
MD
NJ 
NJ 
RI
RI
Passed by one or both Houses
Introduced
Passed & signed by Gov.
To be filed
Enacted into law
*  Bill would require a study of AD inclusion on formularies
**  Bill has been converted or deferred to a study
Source: Presentation by Dan Cohen, CBI’s Abuse Deterrent Formulations Conference, May 19-20, 2015, “Working with
Policymakers and Payers to Improve the Incentives for ADFs” and company data.


21
KP201/APAP Milestones
Human Bioequivalence
Preclinical Abuse Deterrence / Tamper Resistance
Oral Human Abuse Liability Trial
Intranasal Human Abuse Liability Trial
3Q 2015
Intranasal PK Trial
3Q 2015
NDA Submission
2H 2015
NDA Approval (with priority review)
As Early As Mid-2016
DEA Scheduling and Product Launch
As Early As 2017


22
Treatment of Moderate to Severe Pain
KP511/ER Overview


23
KP511/ER Product Overview
KP511/ER is an ER formulation of KP511, a prodrug of hydromorphone
IR bioequivalent release of hydromorphone
demonstrated in rats
Potential valuable properties based on preclinical data
o
Significantly reduced IN and IV bioavailability (abuse deterrence)
o
Highly tamper resistant
o
Limited oral bioavailability at high doses (overdose protection)
Composition-based patent expires in 2032
Potential for POC data in 2016 and utilization of the 505(b)(2) regulatory
pathway


24
KP511/ER Reduced Abuse Potential
Intranasal PK Curves
Intravenous PK Curves
Note: HM refers to hydromorphone
hydrochloride.
Studies conducted in rats.
2.0 mg/kg (hydromorphone eq.)
Average data from 2 studies (N=10)
%-AUC = 25%
%-C
max
= 22%
0.2 mg/kg (hydromorphone eq.)
1 study (N=5)
%-AUC = 5%
%-C
max
= 6%
0
200
400
600
800
1,000
1,200
0
0.2
0.4
0.6
0.8
1
Time [h]
HM (compiled)
KP511 (compiled)
0
10
20
30
40
50
60
0
0.5
1
1.5
2
Time [h]
HM
KP511


25
KP511/ER Potential Oral Overdose Protection
AUC
Note:
HM
refers
to
hydromorphone
hydrochloride.
Studies conducted in rats.
0
500
1,000
1,500
2,000
2,500
3,000
3,500
0
4
8
12
16
20
24
28
32
36
40
44
48
52
56
60
64
Dose [mg/kg HM]
HM·HCl
extrapolated
HM·HCl
(HM)
KP511 (HM)
0
5
10
15
20
25
30
35
0
1
2
3
4
Time [h]


26
Treatment for ADHD
KP415 Overview


27
KP415 Overview
Prodrug of methylphenidate
Branded formulations of methylphenidate (Concerta, Focalin and Ritalin)
accounted
for
sales
of
$1.1
billion
in
2014
(1)
Potential features and benefits
o
Controlled release methylphenidate
o
Reduced abuse potential
o
Suitable for more patient compliant dosage form
Highly water soluble
Oral thin film, orally dissolving tablet, liquid, chewable
Potential for POC data in 2016
(1)
Public filings.


28
KemPharm Expected News Flow
Product
Event
Date
KP201/APAP
Intranasal
Human
Abuse
Liability
Trial
Clinical
Results
3Q 2015
KP201 (API)
Intranasal
PK
Trial
Clinical
Results
3Q 2015
KP201/APAP
NDA Submission
2H 2015
KP201/APAP
NDA Approval (Priority
Review)
As Early As Mid-2016
KP201/APAP
DEA Scheduling and Product Launch
As Early As 2017
KP511/ER
Human POC
2016
KP415
Human POC
2016
KP606/ER
Human POC
2017


29
1Q 2015 Update
Cash of $10.3 million as of March 31, 2015
Net proceeds from IPO in April/May 2015 of $59.9 million, net of underwriting
discounts and commissions
1Q 2015 net loss was $6.0 million vs. $1.9 million for 1Q 2014
o
Increase in net loss year-over-year primarily due to IPO expenses and
KP201/APAP R&D
$35 million available under the $60 million Deerfield facility:
o
$10 million optionally available upon NDA acceptance
o
$25 million optionally available upon NDA approval


For additional information please contact:
Gordon K. “Rusty” Johnson
rjohnson@kempharm.com
319-665-2575